Global Plasmapheresis Market

Plasmapheresis Market Size, Share, Growth Analysis, By Product (Instruments, Disposables), By Technology (Membrane Filtration, Centrifugation), By Procedure (Photopheresis, Ldl Apheresis), By Application (Source Plasma Collection, Therapeutic Plasmapheresis), By End User, By Region - Industry Forecast 2025-2032


Report ID: SQMIG35D2001 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 115 | Figures: 76

Plasmapheresis Market Insights

Plasmapheresis Market size was valued at USD 1.24 Billion in 2023 and is poised to grow from USD 1.34 Billion in 2024 to USD 2.41 Billion by 2032, growing at a CAGR of 7.7% during the forecast period (2025-2032).

Numerous macroeconomic and microeconomic factors are anticipated to have an impact on the worldwide plasmapheresis industry. Growth possibilities for market participants are projected to be brought on by an increase in global healthcare spending, particularly by the Middle East and Asia Pacific's growing emphasis on sophisticated medical care.

In addition to these elements, the market is projected to rise as people become more aware of the various alternatives for treating immune system illnesses, including myasthenia gravis, Guillain-Barre syndrome, Lyell's syndrome, systemic lupus erythematosus, and thrombotic thrombocytopenic purpura.

During the projection period, advancements in plasmapheresis together with expanding treatment options, such as veterinary healthcare, are projected to impact the market's future trajectory.

The worldwide plasmapheresis market is anticipated to grow by roughly 79 BPS between 2022 and 2028. It holds over 35.9% of the market share in the autoimmune disease diagnostic market, which is expected to develop at a 21.1% CAGR over the next several years.

Autoimmune illnesses are more prevalent among humans due to factors including pollution, the flu, and continual population growth. As a result, the demand for plasmapheresis has surged by double digits along with the need for other autoimmune disease therapies.

By the end of 2021, the market value for plasmapheresis had expanded by 4.6% CAGR to USD 1.2 billion. In the previous five years, the global plasmapheresis market produced close to USD 239 million. Additionally, it is anticipated to offer a total potential of more than USD 1.3 billion. The North American plasmapheresis market, which has provided an absolute monetary potential of almost USD 80 million over the past five years, dominates the worldwide industry. Compared to the 4.6% CAGR it saw between 2017 and 2021, the plasmapheresis market is anticipated to increase at a 7.4% CAGR between 2022 and 2028.

US Plasmapheresis Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Plasmapheresis Market size was valued at USD 1.24 Billion in 2023 and is poised to grow from USD 1.34 Billion in 2024 to USD 2.41 Billion by 2032, growing at a CAGR of 7.7% during the forecast period (2025-2032).

The presence of both foreign and domestic industry players has been a defining feature of the plasmapheresis market. To improve their portfolio and market presence, major market players concentrate on methods including innovation and new product releases. In order to promote the expansion of products and services over the next ten years, prominent companies in the global plasmapheresis market are heavily concentrating on R&D. To dominate the market, businesses have used a variety of techniques, including partnerships, mergers, and acquisitions. 'CSL Limited (Australia) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'Grifols, S.A. (Spain) ', 'Baxter International Inc. (United States) ', 'Kedrion S.p.A. (Italy) ', 'Octapharma AG (Switzerland) ', 'Asahi Kasei Medical Co., Ltd. (Japan) ', 'B. Braun Melsungen AG (Germany) ', 'Fresenius SE & Co. KGaA (Germany) ', 'Terumo BCT, Inc. (United States) ', 'Haemonetics Corporation (United States) ', 'Cerus Corporation (United States) ', 'Nikkiso Co., Ltd. (Japan) ', 'Kawasumi Laboratories, Inc. (Japan) ', 'Macopharma SA (France) ', 'Shanghai RAAS Blood Products Co., Ltd. (China) ', 'China Biologic Products Holdings, Inc. (China) ', 'LFB S.A. (France) ', 'Bio Products Laboratory Ltd. (United Kingdom) ', 'Sanquin Blood Supply Foundation (Netherlands) '

During the analysis period, the market for plasmapheresis equipment is likely to experience growth due to the rising prevalence of thrombotic thrombocytopenic purpura, Guillain-Barre syndrome, Myasthenia gravis, diffuse alveolar hemorrhage caused by Goodpasture syndrome, hyperviscosity syndrome, chronic inflammatory demyelinating polyneuropathy, and other autoimmune diseases. Additionally, a better level of end-user knowledge combined with a growing focus on improving healthcare infrastructure is projected to foster market expansion during the assessment period. Plasmapheresis therapy is being more widely used across a variety of end-use sectors as a result of an increase in healthcare spending in several locations. Countries in the Middle East and Africa (MEA) and Asia Pacific are updating their healthcare systems, which is projected to increase demand for cutting-edge treatment methods. These elements are probably going to provide the plasmapheresis business a boost during the evaluation phase.

Plasmapheresis, also known as plasma exchange, is a procedure that involves separating and removing plasma from the blood in order to get rid of a disease component that is present in the plasma. Plasma is needed to treat a variety of illnesses, including anemia, blood loss, gastrointestinal disease, and cancer, which has increased demand for blood donations. Healthcare organizations are always developing plasmapheresis equipment, such as apheresis machines, to offer improvements in these devices and carry out this procedure all over the world. These factors are expected to cause the market to expand during the anticipated period of time.

Due to the increasing awareness among physicians, North America is expected to lead the plasmapheresis industry. Guillain-Barré syndrome, Goodpasture's syndrome, Wegener's granulomatosis, and thrombotic thrombocytopenic purpura (TTP) are among the uncommon disorders that are increasingly being treated using plasmapheresis. The prevalence of chronic illnesses is anticipated to rise, driving the demand for pharmacological treatments that primarily employ plasma products. North America is already experiencing an increase in the market for plasma products. The Plasmapheresis Market is anticipated to be driven by an increase in healthcare spending, an increase in the demand for pharmaceuticals made from plasma, and the incidence of chronic illnesses.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Plasmapheresis Market

Report ID: SQMIG35D2001

$5,300
BUY NOW GET FREE SAMPLE